218 related articles for article (PubMed ID: 37820312)
21. Cope with copper: From copper linked mechanisms to copper-based clinical cancer therapies.
Wang X; Zhou M; Liu Y; Si Z
Cancer Lett; 2023 May; 561():216157. PubMed ID: 37011869
[TBL] [Abstract][Full Text] [Related]
22. Metalloallostery and Transition Metal Signaling: Bioinorganic Copper Chemistry Beyond Active Sites.
Pham VN; Chang CJ
Angew Chem Int Ed Engl; 2023 Mar; 62(11):e202213644. PubMed ID: 36653724
[TBL] [Abstract][Full Text] [Related]
23. Cuproptosis: emerging biomarkers and potential therapeutics in cancers.
Wang M; Zheng L; Ma S; Lin R; Li J; Yang S
Front Oncol; 2023; 13():1288504. PubMed ID: 38023234
[TBL] [Abstract][Full Text] [Related]
24. Cuproptosis and cuproptosis-related genes: Emerging potential therapeutic targets in breast cancer.
Liu X; Luo B; Wu X; Tang Z
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):189013. PubMed ID: 37918452
[TBL] [Abstract][Full Text] [Related]
25. Copper homeostasis and cuproptosis in tumor pathogenesis and therapeutic strategies.
Bian C; Zheng Z; Su J; Chang S; Yu H; Bao J; Xin Y; Jiang X
Front Pharmacol; 2023; 14():1271613. PubMed ID: 37767404
[TBL] [Abstract][Full Text] [Related]
26. The implications and prospect of cuproptosis-related genes and copper transporters in cancer progression.
Zhao Q; Qi T
Front Oncol; 2023; 13():1117164. PubMed ID: 36925927
[TBL] [Abstract][Full Text] [Related]
27. Regulatory roles of copper metabolism and cuproptosis in human cancers.
Wang Z; Jin D; Zhou S; Dong N; Ji Y; An P; Wang J; Luo Y; Luo J
Front Oncol; 2023; 13():1123420. PubMed ID: 37035162
[TBL] [Abstract][Full Text] [Related]
28. Emerging insights into cuproptosis and copper metabolism: implications for age-related diseases and potential therapeutic strategies.
Fan H; Wang K; Zhao X; Song B; Yao T; Liu T; Gao G; Lu W; Liu C
Front Aging Neurosci; 2024; 16():1335122. PubMed ID: 38715962
[TBL] [Abstract][Full Text] [Related]
29. A tumor microenvironment-responsive core-shell tecto dendrimer nanoplatform for magnetic resonance imaging-guided and cuproptosis-promoted chemo-chemodynamic therapy.
Ni C; Ouyang Z; Li G; Liu J; Cao X; Zheng L; Shi X; Guo R
Acta Biomater; 2023 Jul; 164():474-486. PubMed ID: 37040813
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive investigation into cuproptosis in the characterization of clinical features, molecular characteristics, and immune situations of clear cell renal cell carcinoma.
Wang B; Song Q; Wei Y; Wu X; Han T; Bu H; Tang S; Qian J; Shao P
Front Immunol; 2022; 13():948042. PubMed ID: 36275737
[TBL] [Abstract][Full Text] [Related]
31. Cuproptosis, the novel therapeutic mechanism for heart failure: a narrative review.
Yuan HJ; Xue YT; Liu Y
Cardiovasc Diagn Ther; 2022 Oct; 12(5):681-692. PubMed ID: 36329965
[TBL] [Abstract][Full Text] [Related]
32. Multifaceted Roles of Copper Ions in Anticancer Nanomedicine.
Yang S; Song Y; Hu Y; Chen H; Yang D; Song X
Adv Healthc Mater; 2023 Sep; 12(23):e2300410. PubMed ID: 37027332
[TBL] [Abstract][Full Text] [Related]
33. Cuproptosis illustrates tumor micro-environment features and predicts prostate cancer therapeutic sensitivity and prognosis.
Cheng B; Tang C; Xie J; Zhou Q; Luo T; Wang Q; Huang H
Life Sci; 2023 Jul; 325():121659. PubMed ID: 37011878
[TBL] [Abstract][Full Text] [Related]
34. Targeting copper metabolism: a promising strategy for cancer treatment.
Kong R; Sun G
Front Pharmacol; 2023; 14():1203447. PubMed ID: 37564178
[TBL] [Abstract][Full Text] [Related]
35. Cuproptosis-a potential target for the treatment of osteoporosis.
Li D; Gao Z; Li Q; Liu X; Liu H
Front Endocrinol (Lausanne); 2023; 14():1135181. PubMed ID: 37214253
[TBL] [Abstract][Full Text] [Related]
36. Copper Metabolism and Cuproptosis: Molecular Mechanisms and Therapeutic Perspectives in Neurodegenerative Diseases.
Ban XX; Wan H; Wan XX; Tan YT; Hu XM; Ban HX; Chen XY; Huang K; Zhang Q; Xiong K
Curr Med Sci; 2024 Feb; 44(1):28-50. PubMed ID: 38336987
[TBL] [Abstract][Full Text] [Related]
37. Coordination chemistry of mitochondrial copper metalloenzymes: exploring implications for copper dyshomeostasis in cell death.
Shim D; Han J
BMB Rep; 2023 Nov; 56(11):575-583. PubMed ID: 37915136
[TBL] [Abstract][Full Text] [Related]
38. Cuproptosis scoring system to predict the clinical outcome and immune response in bladder cancer.
Song Q; Zhou R; Shu F; Fu W
Front Immunol; 2022; 13():958368. PubMed ID: 35990642
[TBL] [Abstract][Full Text] [Related]
39. Syphilis mimetic nanoparticles for cuproptosis-based synergistic cancer therapy via reprogramming copper metabolism.
Zhang J; Han M; Zhang J; Abdalla M; Sun P; Yang Z; Zhang C; Liu Y; Chen C; Jiang X
Int J Pharm; 2023 Jun; 640():123025. PubMed ID: 37164186
[TBL] [Abstract][Full Text] [Related]
40. The molecular mechanisms of cuproptosis and its relevance to cardiovascular disease.
Wang D; Tian Z; Zhang P; Zhen L; Meng Q; Sun B; Xu X; Jia T; Li S
Biomed Pharmacother; 2023 Jul; 163():114830. PubMed ID: 37150036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
